BriaCell Therapeutics Corp. announced a best-efforts offering of 1,449,300 common shares at $3.25 each, aiming to raise approximately $4.7 million before fees. The funds will support working capital, general corporate purposes, and advancing their cancer immunotherapy programs. The offering is expected to close on June 2, 2026, and is conducted under a shelf registration with the SEC. This capital raise is crucial for BriaCell as it continues developing novel treatments in immuno-oncology to improve cancer care outcomes.
Atlas Salt Inc. announced a $10 million bought deal financing agreement with Ventum Financial Corp. and Raymond James Ltd. to sell 8.33 million shares at $1.20 each, with an option to sell an additional 15%. The funds will support site preparation, e...
The US Department of Commerce has closed a loophole that allowed advanced AI chips from Nvidia and AMD to be exported to Chinese companies operating outside China, such as in Malaysia. This move strengthens US efforts to restrict China's access to cr...
Nebius Group has surged 1,000% since early 2025, driven by aggressive expansion in AI data centers. The company aims to exceed 4 GW of contracted power by year-end, potentially generating $36 billion in annual recurring revenue (ARR), far above initi...
Ethereum (ETH) price remains stable near the lower end of its range despite growing short interest above current levels, signaling a potential short squeeze. Large holders (whales) continue accumulating ETH even during price dips, contrasting with ca...
In May, XRP inflows to Binance dropped sharply to 215 million XRP, the lowest since early 2026, indicating reduced short-term selling intent among holders. This decline aligns with more stable price action and lower volatility, suggesting fewer XRP h...
